CD70-targeted CAR-T for relapsed lymphoma with CD70
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies a type of immune therapy called CD70-targeted CAR-T for people whose lymphoma has come back or did not respond after standard treatments. It may help by training your own T cells to recognize and attack lymphoma cells that carry the CD70 marker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18–75, and your expected survival is more than 3 months
- Your lymphoma type is confirmed by biopsy, and it must be a CD70-positive relapsed or refractory form
- Your lymphoma must have had at least two rounds of whole-body (systemic) treatment before enrolling
- Your lymphoma cells must show CD70 on at least 10% of cells (based on testing)
- You must be well enough to handle treatment (specific blood counts and heart/lung function limits)
- You can have cells collected (leukapheresis), and doctors must see at least one measurable tumor spot on CT or MRI
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CD70 CAR T cells, which are specially designed immune cells that target a protein called CD70 on cancer cells. It is for people with certain types of lymphoma, myeloma, kidney cancer, or sarcoma that has come back or not responded to other treatments.
This trial tests a new type of immunotherapy called CAR-T that targets a protein called CD7 on cancer cells. It is for people with peripheral T-cell lymphoma that has come back or not responded to at least one prior treatment.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called CD19 on your lymphoma cells. It's for people whose B-cell lymphoma has returned or not responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
This study tests a new kind of CAR-T cell therapy for people with certain types of B-cell lymphoma that have come back or not improved after standard treatments. The CAR-T cells have been modified to turn off two genes (BCOR and ZC3H12) to make them work better against the cancer.
This trial tests an experimental CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to find and attack cancer cells.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.